Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359221079125
Abstract: Introduction: Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) that is approved for the use of EGFR-mutant non-small cell lung cancer (NSCLC) patients. In this study, we investigated the acquired resistance mechanisms in NSCLC… read more here.
Keywords: preclinical models; patients patient; resistance; patient derived ... See more keywords